# Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

> **NCT03070899** · PHASE3 · COMPLETED · sponsor: **ObsEva SA** · enrollment: 526 (actual)

## Conditions studied

- Uterine Fibroids
- Heavy Menstrual Bleeding

## Interventions

- **DRUG:** OBE2109
- **DRUG:** Placebo to match OBE2109
- **DRUG:** Placebo to match Add-back
- **DRUG:** Add-back

## Key facts

- **NCT ID:** NCT03070899
- **Lead sponsor:** ObsEva SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-20
- **Primary completion:** 2020-04-14
- **Final completion:** 2021-04-12
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2021-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03070899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03070899, "Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03070899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*